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Abstract  
Aim: To estimate the absolute risk (%) of 5- and 10-years cardiovascular mortality in Macedonian type 2 
diabetes patients based on DECODE model, and the gender difference of the estimated risk.  
Methods and materials: Observational, cross-sectional study including a cohort of 1,404 type 2 diabetes 
patients; inclusion criteria:  aged 25 to 65 years, absence of confirmed arterial disease, history of ischaemic 
heart disease, cerebrovascular disease or peripheral arterial disease; and absence of life-threatening conditions, 
such as cancer; at the time of risk assessment. Absolute risk was assessed based on the following risk factors:  
gender, age, known diabetes, smoking status, systolic blood pressure and total cholesterol.  
Results:  From the study cohort, 884 were identified as eligible for analysis, 503 (56.9%) of these were women. 
The estimated absolute risk (%) of 5- and 10-year cardiovascular mortality, based on DECODE model, was 1.1 
± 1.3% and 5.5 ± 6.1%, respectively; significantly higher absolute risk was estimated in men (1.7 ± 1.6 vs 0.6 
± 0.8, p  <  0.001 and 8.9 ± 7.6 vs 2.9 ± 2.5, p  <  0.001, for 5- and 10-years absolute risk, respectively).  
Discussion and conclusion: This study is a first assessment of cardiovascular mortality in the Macedonian type 
2 diabetic population based on DECODE model. It would be of both clinical and scientific interest to assess the 
risk prediction accuracy of the model, and to compare it with other diabetes-specific and diabetes non-specific 
models. 
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Introduction 
The number of people with type 2 diabetes 
is increasing worldwide, and the total number is 
expected to rise to 552 million in 2030 [1]. The 
increased prevalence of type 2 diabetes is mainly 
due to longer life expectancy and the steep rise in 
obesity prevalence caused by a sedentary lifestyle. 
Based on the International Diabetes Federation 
(IDF) estimates, there were 136,700 people with 
diabetes mellitus in the Republic of Macedonia in 
2012, and this number is projected to increase to 
166,000 by 2030 [1].  
Cardiovascular disease (CVD) is the main 
cause of mortality in people with type 2 diabetes: it 
is estimated that 75–80% of people with diabetes 
die of cardiovascular events, and the risk of coron-
ary artery disease in this population is two to four 
times higher compared to the non-diabetic popula-
tion [2, 3]. 
Absolute risk assessment of CVD based on 
several risk factors is necessary, such as: 1) CVD 
is of multifactorial origin; 2) risk factors occur 
concomitantly; 3) concomitant risk factors exhibit 
multiplicative effect on the CVD risk [4]. Hence, 
for the certain level of a single risk factor, absolute 
CVD risk can vary considerably depending on the 
level of other risk factors.  
There are several risk assessment models 
based on the general population data, or diabetes 
non-specific models, such as the Framingham 
model, [4, 5–11] and risk assessment models spe-
cific for the diabetic population, the most widely 
used being the United Kingdom Prospective Dia-
betes Study (UKPDS) model [12–16].  
Diabetes Epidemiology: Collaborative Ana-
lysis of Diagnostic Criteria in Europe (DECODE). 
The Study Group developed a model for risk asses-
sment of fatal CVD incorporating glucose tole-
rance status and fasting plasma glucose [10]. The 
DECODE model was developed based on a large 
European DECODE cohort assessing cardiovas-
110 Smokovski I, Milenkovic T 
cular mortality over 5-year and 10-year follow-up 
periods. In addition to the classical cardiovascular 
risk factors, the DECODE model is unique as it 
includes, besides known diabetic status, glucose 
concentrations within the pre-diabetes range, such 
as Impaired Fasting Glucose (IFG) and Impaired 
Glucose Tolerance (IGT) [10].  
The DECODE cohort included 16,506 men 
and 8,907 women from 14 European studies. The 
DECODE risk assessment model was developed 
based on a major epidemiological DECODE study 
including the following risk factors: age, fasting 
and 2h glucose (including cases of known diabe-
tes), fasting glucose alone (including cases of 
known diabetes), cholesterol, smoking status and 
systolic blood pressure [10]. Despite the magni-
tude of the diabetes problem, threatening to beco-
me the largest pandemic mankind has ever faced, 
and its close relation to cardiovascular morbidity 
and mortality, no study has so far been reported on 
the risk assessment of cardiovascular mortality in 
the Macedonian type 2 diabetes population using 
the DECODE model. 
The aim of this study is to estimate the 
absolute risk (%) of 5- and 10-year cardiovascular 
mortality in Macedonian type 2 diabetes patients 
based on the DECODE model, and the gender dif-
ference of the estimated risk. Additionally, this 
study evaluates the cardiovascular risk factors and 
estimated absolute risk (%) of 5- and 10-year car-
diovascular mortality based on the DECODE model 
across glycated haemoglobin (HbA1c) quartiles; 
and the cardiovascular risk factors across the quar-
tiles of estimated absolute risk (%) of 5- and 10-
year cardiovascular mortality based on DECODE 
model. 
 
Materials and methods 
This is an observational, cross-sectional 
study including a cohort of 1,404 type 2 diabetes 
patients from the Republic of Macedonia, who 
were prescribed insulin treatment and whose pa-
rameters were recorded at the time of insulin 
treatment prescription, in the period from Septem-
ber 2002 till January 2004.  
All diagnostic and therapeutic procedures in 
the study patients were within the scope of routine 
clinical practice, hence the study is non-interven-
tional (observational). Patients were prescribed 
insulin treatment due to inadequate glycaemic con-
trol after previous adjustments of their diet, phy-
sical activity and/or administered oral anti-diabetic 
treatment. 
Criteria for inclusion of type 2 diabetes pa-
tients from the study cohort in the analysis include: 
age of 25 to 65 years, absence of confirmed arterial 
disease, history of ischaemic heart disease, cerebr-
ovascular disease or peripheral arterial disease, and 
absence of life-threatening conditions, such as 
cancer, at the time of risk assessment. The above 
inclusion criteria were selected in this study to 
obtain results with the DECODE model, that will 
be comparable with the results of other risk asses-
sment models, such as UKPDS, reported to demons-
trate the most precise cardiovascular risk asses-
sment within the above-mentioned criteria [12]. 
The risk score for cardiovascular mortality, 
over 5 and 10 years of follow-up, were calculated 
based on the risk score coefficients for gender, age 
range, known diabetes, smoking status, systolic 
blood pressure range and total cholesterol range, as 
described in the DECODE model [10].  
The DECODE model for cardiovascular risk 
assessment includes glucose concentrations within 
pre-diabetes range, such as Impaired Fasting Gluc-
ose (IFG) and Impaired Glucose Tolerance (IGT) 
[10], however such an extended glucose concen-
tration range was of no significance for this study, 
as all patients of the study cohort had already been 
diagnosed with type 2 diabetes. 
Absolute risk of cardiovascular mortality for 
an individual was calculated from the risk score, 
using the equation:  
 
M х [1 – Sexp(risk score/10)], 
 
where parameter M stands for Multiplying factors 
and S for Survival factors [10].  
Multiplying factors were used as for an 
Eastern European country in the DECODE model 
(Men 2.87, Women 2.61), and Survival factors 
were used as for 5-year and 10-year follow-ups, 
namely 0.998873 and 0.997508, respectively [10]. 
Risk assessment of 5-year and 10-year car-
diovascular mortality with the DECODE model was 
performed with the parameters valid at the time 
when patients were prescribed insulin treatment. 
In order to investigate the effect of the level 
of glycaemic control, as reflected by the HbA1c 
value, cardiovascular risk factors and estimated 
absolute risk of 5- and 10-year cardiovascular mor-
tality based on the DECODE model were presen-
ted across HbA1c quartiles. Additionally, cardio-
vascular risk factors were presented across quar-
tiles of estimated absolute risk of 5- and 10-year 
cardiovascular mortality based on the DECODE 
model. 
The Statistical Package for Social Sciences 
(SPSS) was used for statistical analysis, including 
descriptive statistics, Student t-test and Chi-square 
test. A p value of less than 0.05 was considered 
statistically significant. 
 
Results 
From the study cohort of 1,404 type 2 dia-
betes patients, 884 were identified as eligible for 
the analysis by fulfilling the inclusion criteria. 
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Cardiovascular risk factors and estimated absolute 
risk (%) of 5- and 10-year cardiovascular mortality 
in men and women based on the DECODE model 
are presented in Table 1. 
 
Table 1 
 
Cardiovascular risk factors and estimated absolute risk (%) of 5- and 10-years cardiovascular mortality in men  
and women based on DECODE model 
 
 
 Total Men Women p-value 
Number (%) 884 (100) 381 (43.1) 503 (56.9)  
Age (years) * 48.6 ± 7.2 47.9 ± 7.4 49.2 ± 7.0 < 0.01 
HbA1c (%) * 9.5 ± 2.1 9.4 ± 2.0 9.6 ± 2.1 NS 
Systolic Blood Pressure (mmHg) * 143.7 ± 20.7 138.6 ± 18.6 147.6 ± 21.4 < 0.001 
Total Cholesterol (mmol/l) * 6.1 ± 1.3 6.0 ± 1.3 6.1 ± 1.3 NS 
Smokers (%) 323 (36.5) 206 (54.1) 117 (23.3) < 0.001 
DECODE 5-years risk (%) *  1.1 ± 1.3 1.7 ± 1.6 0.6 ± 0.8 < 0.001 
DECODE 10-years risk (%) * 5.5 ± 6.1 8.9 ± 7.6 2.9 ± 2.5 < 0.001 
* Mean ± standard deviation; NS = non-significant  
 
Out of 884 study patients, 503 (56.9%) were 
women. The estimated absolute risk (%) of 5- and 
10-year cardiovascular mortality based on the DE-
CODE model was 1.1 ± 1.3% and 5.5 ± 6.1%, res-
pectively. Age and systolic blood pressure were 
significantly higher in women (49.2 ± 7.0 vs 47.9 
± 7.4, p < 0.01, and 147.6 ± 21.4 vs 138.6 ± 18.6, p 
< 0.001, respectively), the number of smokers was 
significantly higher in men (206 (54.1%) vs 117 
(23.3%), p < 0.001), while there was no difference 
in total cholesterol (6.0 ± 1.3 vs 6.1 ± 1.3, p = NS) 
and HbA1c value (9.4 ± 2.0 vs 9.6 ± 2.1, p = NS). 
There was a statistically significant difference in 
the estimated absolute risk (%) of both 5- and 10-
year cardiovascular mortality based on the DE-
CODE model between the genders; in both follow-
up periods, a higher absolute risk was estimated in 
men (1.7 ± 1.6 vs 0.6 ± 0.8, p < 0.001 and 8.9 ± 
7.6 vs 2.9 ± 2.5, p < 0.001, for 5- and 10-year 
absolute risk, respectively). 
Cardiovascular risk factors and estimated 
absolute risk (%) of 5- and 10-year cardiovascular 
mortality based on the DECODE model across 
HbA1c quartiles are presented in Table 2. 
 
Table 2 
 
Cardiovascular risk factors and estimated absolute risk (%) of 5- and 10-years cardiovascular mortality based 
on DECODE model across HbA1c quartiles 
 
 HbA1c 
 1st Quartile 2nd Quartile 3rd Quartile  4th Quartile  
Number (Men/Women)  
(% of total) 
223 (97/126) 
(25.2) 
210 (102/108) 
(23.8) 
233 (103/130) 
(26.4) 
218 (79/139) 
(24.6) 
Age (years) * 49.4 ± 6.9 48.5 ± 6.9 48.6 ± 7.1 47.9 ± 7.9 
HbA1c (%) * 7.1 ± 0.9 8.7 ± 0.4 9.9 ± 0.4 12.2 ± 1.4 
Systolic Blood Pressure (mmHg) * 146.4 ± 20.9 143.4 ± 18.5 143.5 ± 19.6 141.4 ± 23.3 
Total Cholesterol (mmol/l) * 6.0 ± 1.4 6.2 ± 1.3 6.1 ± 1.3 5.9 ± 1.1 
Smokers (% of total) 84 (26.0) 89 (27.6) 84 (26.0) 66 (20.4) 
DECODE 5-years risk (%) *  1.2 ± 1.3 1.3 ± 1.6 1.1 ± 1.3 0.9 ± 1.1 
DECODE 10-years risk (%) * 6.0 ± 6.2 6.4 ± 7.5 5.4 ± 5.7 4.3 ± 4.7 
* Mean ± standard deviation 
 
The highest (4th) quartile of HbA1c (12.2 ± 
1.4%) was associated with the lowest age (47.9 ± 
7.9 years), lowest systolic blood pressure (141.4 ± 
23.3 mmHg), lowest value of total cholesterol (5.9 
± 1.1 mmol/l), and lowest number of smokers (n = 
66, 20.4% of total number of smokers). The estim-
ated absolute risk (%) of 5- and 10-year cardiovas-
cular mortality based on the DECODE model was 
lowest in the 4th quartile of HbA1c (0.9 ± 1.1 and 
4.3 ± 4.7, for 5- and 10-year absolute risk, respec-
tively). 
Cardiovascular risk factors across quartiles 
of estimated absolute risk (%) of 5- and 10-year 
cardiovascular mortality based on the DECODE 
model are presented in Table 3. 
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Table 3 
 
Cardiovascular risk factors across quartiles of estimated absolute risk (%) of 5- and 10-years cardiovascular 
mortality based on DECODE model 
 
 DECODE 5-years cardiovascular mortality DECODE 10-years cardiovascular mortality 
 1st Quartile 2nd Quartile 3rd Quartile  4th Quartile  1st Quartile 2nd Quartile 3rd Quartile  4th Quartile 
Number 
(Men/Women)              
(% of total) 
222 (0/222) 
(25.1) 
207 (99/108) 
(23.4) 
232 (125/107) 
(26.2) 
223 (157/66)  
(25.2) 
223 (0/223) 
(25.2) 
234 (78/156) 
(26.5) 
200 (123/77) 
(22.6) 
227 (180/47) 
(25.7) 
Age (years) * 43.3 ± 4.6 47.4 ± 6.9 49.1 ± 6.8 54.4 ± 5.5 44.3 ± 5.5 48.3 ± 6.7 48.1 ± 7.8 53.6 ± 5.6 
HbA1c (%) * 9.8 ± 2.1 9.6 ± 2.0 9.4 ± 2.2 9.2 ± 1.8 9.8 ± 2.1 9.5 ± 2.0 9.4 ± 2.2 9.2 ± 1.8 
Systolic Blood 
Pressure (mmHg) * 141.6 ± 19.6 135.5 ± 19.3 146.7 ± 20.9 150.3 ± 20.1 139.5 ± 20.8 143.6 ± 19.8 141.2 ± 21.1 150.1 ± 19.7
Total Cholesterol 
(mmol/l) * 6.1 ± 1.3 5.8 ± 1.2 6.0 ± 1.1 6.3 ± 1.5 5.9 ± 1.0 6.0 ± 1.3 6.2 ± 1.4 6.2 ± 1.4 
Smokers (% of total) 32 (9.9) 38 (11.8) 110 (34.1) 143 (44.3) 16 (5.0) 39 (12.1) 116 (35.9) 152 (47.1) 
DECODE 5-years 
risk (%) *  0.1 ± 0.04 0.5 ± 0.1 1.0 ± 0.2 2.8 ± 1.6 0.1 ± 0.08 0.5 ± 0.2 1.0 ± 0.3 2.8 ± 1.6 
DECODE 10-years 
risk (%) * 1.2 ± 0.5 2.5 ± 0.8 4.7 ± 1.2 13.3 ± 7.6 1.2 ± 0.4 2.6 ± 0.6 4.8 ± 0.8 13.4 ± 7.5 
* Mean ± standard deviation  
 
The highest (4th) quartiles of both DECODE 
5- and 10-year cardiovascular mortality risk esti-
mation were associated with the highest age (54.4 
± 5.5 and 53.6 ± 5.6 years, respectively), highest 
systolic blood pressure (150.3 ± 20.1 and 150.1 ± 
19.7 mmHg, respectively), highest total cholesterol 
(6.3 ± 1.5 and 6.2 ± 1.4 mmol/l, respectively), 
highest number of smokers (n = 143, 44.3% of 
total, and n = 152, 47.1% of total, respectively) 
and lowest HbA1c value (9.2 ± 1.8 and 9.2 ± 
1.8%, respectively). The estimated absolute risk of 
5-year cardiovascular mortality was highest in the 
4th quartile of DECODE 10-years cardiovascular 
mortality risk estimation (2.8 ± 1.6%), and estima-
ted absolute risk of 10-year cardiovascular morta-
lity was highest in the 4th quartile of the DECODE 
5-year cardiovascular mortality risk estimation 
(13.3 ± 7.6%). There were no men (n = 0) in the 
first quartiles of both DECODE 5- and 10-year 
cardiovascular mortality risk estimation. 
 
Discussion and conclusion 
One of the key points of the most recent 
Position Statement of the American Diabetes As-
sociation (ADA) and the European Association for 
the Study of Diabetes (EASD) on the management 
of hyperglycaemia in type 2 diabetes, was that 
comprehensive cardiovascular risk reduction must 
be a major focus of therapy [17]. In addition, the 
joint European Society of Cardiology (ESC) Gui-
delines strongly recommend the use of risk asses-
sment models confirming the advantages of their 
use, such as: intuitiveness, models taking into ac-
count the multifactorial nature of cardiovascular 
disease, allowing flexibility in management – if an 
ideal risk factor level cannot be achieved then the 
total risk can still be reduced by reducing other 
risk factors, a more objective assessment of the 
risk over time, and a common language of risk for 
clinicians [18]. 
The EASD recommends using Framingham 
and DECODE as the preferred prediction models 
for calculating CVD risk in type 2 diabetes patients 
[10, 19, 20]. This study is a first assessment of 
cardiovascular mortality in the type 2 diabetic 
population in Macedonia based on the DECODE 
model, and is a first step towards external valida-
tion of the DECODE model, taking into conside-
ration that the original DECODE study did not 
include any Macedonian population. Studies of 
cardiovascular risk assessment in the type 2 diab-
etes Macedonian population with other diabetes-
specific and diabetes non-specific models have 
already been reported [21, 22].  
The estimated absolute risk (%) of 5- and 
10-year cardiovascular mortality based on the 
DECODE model was 1.1 ± 1.3% and 5.5 ± 6.1%, 
respectively, in both follow-up periods being sig-
nificantly higher in men than in women (5-years: 
1.7 ± 1.6% vs 0.6 ± 0.8%, p < 0.001; 10-years: 8.9 
± 7.6% vs 2.9 ± 2.5%, p < 0.001), despite signifi-
cantly higher age and systolic blood pressure in 
women, and no difference in HbA1c value and 
total cholesterol. The number of smokers was sig-
nificantly higher in men than in women, and 
jointly with gender, appears as the strongest pre-
dictor of the cardiovascular mortality in our study. 
Correlation of male gender with cardiovascular 
mortality was additionally confirmed by the absen-
ce of men (n = 0) in the lowest (1st) quartiles of 
Risk assessment of cardiovascular mortality in Macedonian type 2… 113 
both DECODE 5- and 10-year cardiovascular mor-
tality risk estimation, and the fact that 5-year and 
10-year cardiovascular mortality risk calculated 
with the DECODE model were 2.8 times and 3.1 
times, respectively, higher in men than in women. 
However, while women appear to be at lower 
CVD risk than men, this could be misleading as 
the risk is only deferred for a certain time period 
rather than avoided [18].  
In comparison, the 5-year CVD mortality of 
the total DECODE study population was 1.8% in 
male and 0.6% in female patients; and 10-year 
CVD mortality was 3.8% and 1.8% in male and 
female patients, respectively [10]. The lower CVD 
mortality rate after 10 years follow-up in the 
DECODE study population compared to the fatal 
CVD absolute risk assessment in our study could 
be attributed to the fact that the DECODE 
population consisted of not only diabetic but also 
pre-diabetic population where the CVD risk is 
lower compared to the diabetic population, whe-
reas in our study all patients analysed were dia-
gnosed with type 2 diabetes. 
A limitation of the DECODE equation is 
that it incorporates diabetes, IFG and IGT, based 
on fasting plasma glucose and/or 2-hour post-
prandial glycaemia in a categorical fashion, and 
thus does not adequately consider the effect of dif-
ferent levels of glycaemia [23]. Such a finding has 
also been confirmed in our study:  the estimated 
absolute risk (%) of 5- and 10-year cardiovascular 
mortality based on the DECODE model was lowest 
in the highest (4th) quartile of HbA1c (0.9 ± 1.1% 
and 4.3 ± 4.7%, respectively for 5- and 10-year 
absolute risk) (Table 2), and inversely, the highest 
(4th) quartiles of both DECODE 5- and 10-year 
cardiovascular mortality risk estimation were 
associated with the lowest HbA1c value (9.2 ± 
1.8% and 9.2 ± 1.8%, respectively) (Table 3). This 
is in contrast with the risk assessment of diabetes-
specific models, e.g. UKPDS, that incorporate gly-
caemic control as a continuous variable (HbA1c 
value), and other diabetes-specific parameters such 
as age at diagnosis of diabetes and duration of dia-
betes, where the predicted risk is closely related to 
the HbA1c level [12].  
It should be noted that although EASD re-
fers to the DECODE prediction model, it has been 
validated only once, with moderate performance; 
and no Macedonian population was included in the 
validation [23]. Since this study provides informa-
tion on the cardiovascular risk assessment with the 
DECODE model in the Macedonian diabetic 
population, it would be of both clinical and scien-
tific interest to assess its prediction accuracy, or 
prognostic value, and to compare it with other dia-
betes-specific and diabetes non-specific models.  
The clinical benefit of the cardiovascular 
risk assessment models is achieved through their 
ability to inform on the potential for risk reduction, 
and to convey the expected benefit of treatment to 
patients. In this context, models such as DECODE 
can be used as preventive and motivating tools for 
behavioural changes, especially in patients with 
type 2 diabetes.  
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Цел: Да се процени апсолутниот ризик (%) за 
5 и 10-годишниот кардиоваскуларен морталитет кај 
македонски пациенти со дијабетес тип 2 врз основа 
на DECODE моделот, како и да се одреди разликата 
во проценетиот ризик помеѓу половите. 
Меtоди и маtеријали: Опсервациска, крос-
секциска студија на кохорта од 1.404 пациенти со 
дијабетес тип 2; инклузиони критериуми: возраст од 
25 до 65 години, отсуство на потврдено артериско 
заболување, историја на исхемично срцево заболу-
вање, цереброваскуларно заболување или перифер-
но артериско заболување; како и отсуство на жи-
вотно-загрозувачката состојба, како канцер; во мо-
ментот на процена на ризикот. Апсолутниот ризик 
беше проценет врз основа на следниве ризик фак-
тори: пол, возраст, познат дијабетес, пушење, систо-
лен крвен притисок и вкупен холестерол.  
Резулtаtи: Од студиската кохорта, 884 беа 
идентификувани за анализа, 503 (56,9%) од нив беа 
жени. Проценетиот апсолутен ризик (%) за 5 и 10-
годишниот кардиоваскуларен морталитет базиран 
на DECODE моделот беше 1,1 ± 1,3% и 5,5 ± 6,1%, 
соодветно; сигнификантно повисок апсолутен ризик 
беше проценет кај мажите (1,7 ± 1,6 vs 0,6 ± 0,8, p < 
0,001 и 8,9 ± 7,6 vs 2,9 ± 2,5, p < 0,001, за 5 и 10-
годишниот апсолутен ризик, соодветно).  
Дискусија и заклучок: Оваа студија е прва 
процена на кардиоваскуларниот морталитет кај 
македонска тип 2 дијабетична популација врз 
основа на DECODE моделот. И од клинички и од 
научен интерес е важно да се процени прецизностa 
на моделот во проценувањето на ризикот и да се 
спореди со другите дијабетес-специфични и дијабе-
тес-неспецифични модели. 
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